Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & ESMO GI 2025 Highlights Webinar
Featuring presentations & discussions on selected GI cancer abstracts from the 2025 American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) GI Cancer Annual Meetings.
Chair: Lorenza Rimassa | Moderators: Richard D Kim, Filippo Pietrantonio, Efrat Dotan
Session 1: Latest in colorectal cancer
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
Dirk Arnold Asklepios Tumorzentrum, Hamburg, Germany
ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG)
Jeanne Tie The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Health-related quality of life (HRQoL) analyses from CheckMate 8HW (Abstract 1O)
Elena Élez Fernández Vall d’Hebron Institute of Oncology, Barcelona, Spain
Panel discussion
Session 2: Developments in gastroesophageal cancer
Event-free survival (EFS) in MATTERHORN: A randomized, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
Yelena Janjigian Memorial Sloan Kettering Cancer Center, NY, United States
Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase III DESTINY-Gastric04 study
Kohei Shitara National Cancer Center Hospital East, Kashiwa, Japan
Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase III, randomized LEAP-015 study
Sylvie Lorenzen Technical University of Munich, Munich, Germany
Panel discussion
Session 3: Advances in pancreatic and hepatobiliary cancers
PANOVA-3: Phase III study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC)
Vincent Picozzi Virginia Mason Franciscan Health, Seattle, WA, United States
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial
Thorsten Götze University Cancer Center Frankfurt, Germany
Safety results from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis
Stephen Lam Chan Chinese University of Hong Kong, Hong Kong
Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study
Andrea Casadei Gardini University Vita-Salute San Raffaele, School of Medicine, Milan, Italy
Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d/c) due to treatment-related adverse events (TRAEs): Results from CheckMate 9DW
Thomas Decaens University Grenoble-Alpes, France
Panel discussion
